Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month
Eli Lilly is looking to get ahead of any more federal action on insulin prices, announcing today that it will not only slash its most commonly used insulin by 70%, but cap out-of-pocket costs for those on commercial insurance at $35 per month — just as the federal government recently did for those insured by Medicare.
The move to again slash the cost of insulin — back in 2019, Lilly cut the list price of Humalog by 50% — comes as rationing of the life-saving shot has led to deaths for some diabetics who could not afford their injections, even as Congress is working on another push to cap out-of-pocket costs for diabetics after Senate Republicans shot down the idea last August.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.